NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Nivolumab|DRUG: Ipilimumab
Sponsor: Dana-Farber Cancer Institute
Collaborators: Bristol-Myers Squibb